SCHEMBL169803

SCHEMBL169803

Cc1cccc(NS(C)(=O)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.59
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PTGS1 P23219 1/20 0.56
PTGS2 P35354 1/20 0.56
HPGD P15428 1/20 0.56
CYP3A4 P08684 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
POLB P06746 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
IDO1 P14902 1/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
HSP90AA1 P07900 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698855 0.87 KEAP1 (0.70) KEAP1ALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL14534371 0.82 CA1 (0.59) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL31539189 0.82 HPGD (0.54) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL27278148 0.82 HPGD (0.54) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL11786328 0.80 HPGD (0.53) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL11786334 0.80 HPGD (0.53) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL10192105 0.80 HPGD (0.53) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
Methane SCHEMBL11428234 0.80 HPGD (0.53) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9
SCHEMBL14582129 0.80 NPSR1 (0.57) KEAP1ALDH1A1SMN1; SMN2HPGDCYP3A4
SCHEMBL10191952 0.80 HPGD (0.53) ALDH1A1SMN1; SMN2HPGDCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822530-B2 Sulfur derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2014-09-02 US claimed
US-20130190338-A1 SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-07-25 US claimed
EP-0658169-A1 DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES SCHERING CORPORATION (US) 1995-06-21 EP claimed
US-5298492-A Inhibitors of endopeptidase and treatment of cardiovascular disorders SCHERING CORPORATION (US) 1994-03-29 US claimed
WO-1994003481-A1 DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES SCHERING CORPORATION (US) 1994-02-17 WO claimed
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR MEDSHINE DISCOVERY INC. (CN) 2023-11-02 US disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230303501-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 US disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases FINK CYNTHIA A 2007-03-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7157580-B2 Aminopyrimidine and aminopyridine anti-inflammation agents ROCHE PALO ALTO LLC (US) 2007-01-02 US disclosed
US-7157580-B2 Aminopyrimidine and aminopyridine anti-inflammation agents ROCHE PALO ALTO LLC (US) 2007-01-02 US disclosed
WO-2006030032-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-23 WO disclosed
EP-0495594-A1 Sulphonamide derivatives ZENECA LIMITED (GB) 1992-07-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR CRBN, CRKL, NCOR1 KEAP1 1226/4885ALDH1A1 4261/4885SMN1; SMN2 2827/4885
US-20230303501-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME ABL1, ABL2, MUSK KEAP1 1048/4885ALDH1A1 1314/4885SMN1; SMN2 39/4885
US-20130190338-A1 SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CX3CR1, CXCR2, CCR2 KEAP1 946/4885ALDH1A1 2553/4885SMN1; SMN2 4664/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KEAP1 3516/4885ALDH1A1 4428/4885SMN1; SMN2 4764/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A KEAP1 508/4885ALDH1A1 433/4885SMN1; SMN2 3998/4885
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases BRAF, RAF1, NRAS KEAP1 267/4885ALDH1A1 1890/4885SMN1; SMN2 4098/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 KEAP1 1700/4885ALDH1A1 3447/4885SMN1; SMN2 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.